Emerade Injection (Adrenaline Tartrate)

Each pre-filled Emerade injection pen is designed for single-use only and entire contents of the pen should be injected. The pre-filled pen contains 0.5 ml of adrenaline solution 1 mg/ml. Emerade 150 micrograms delivers a single dose of 0.15 ml containing 150 micrograms of adrenaline (as tartrate). Each 0.15 ml (150 micrograms) dose contains 0.075 mg sodium meta-bisulphite (E223).

There is the risk of drug interactions between Emerade and other medications, and the risk is most primarily in the way certain types of medications may enhance the effects of adrenaline when present in the body at the same time. Medications that may have negative interactions with Emerade include: Tricyclic antidepressants like Asendin, Norpramin, Tofranil, Anafranil, and Elavil, among others, Monoamine oxidase (MAO) inhibitors like Marplan, Nardil, Emsam, and Parnate, among others, Catechol-O-methyl transferase (COMT) inhibitors like Comtan (entacapone), Tasmar (tolcapone), and Ongentys (opicapone) used to treat Parkinson’s disease, among others Speak to your physician if you haveanyconcerns about the possibility of negative drug interactions between Emerade and other medications you are also currently on. The adrenaline in Emerade must also be used with caution for patients receiving halogenated hydrocarbons and related medications that make the person’s heart more sensitive to arrhythmias. Administering fast-acting vasodilators or alpha blockers can counteract the affects of Emerade’s adrenaline on blood pressure. Beta blockers can inhibit the stimulating affects of the adrenaline in Emerade. The hyperglycaemic effect of adrenaline may necessitate an increase in insulin or oral hypoglycaemic treatment in diabetic patients.